Treatment for myocarditis with heart failure by the inhibitory Fc receptor of immunoglobulin

免疫球蛋白疗法已用于治疗一级和二级抗体缺乏症超过25年。它是一种安全的制剂，无长期副作用。虽然作用方式尚不清楚，但该药物被认为具有有效的免疫调节和抗炎作用。近年来，我们发现免疫球蛋白治疗对伴有心力衰竭的心肌疾病是有益的。在基本方面，已经发现用于实验性病毒性和非病毒性心肌炎的免疫球蛋白疗法不仅通过Fab部分的抗病原体作用有效，而且通过Fc部分的抗病毒作用有效。此外，该药物对治疗实验性小鼠心肌功能障碍是有用的。在临床方面，研究了免疫球蛋白治疗暴发性心肌炎和急性扩张型心肌病的效果。免疫球蛋白管理是非常有用的治疗这些患者。也就是说，虽然研究人群较小，但药物显示出对活动性心肌损伤伴心肌功能障碍的潜在有益作用，患者的左心室射血分数通过治疗得以恢复。因此，免疫球蛋白治疗心脏病患者似乎是一种新的和有效的治疗策略。

Immunoglobulin therapy has been used for the treatment of primary and secondary antibody deficiency for more than 25 years. It is a safe preparation with no long-term side effect. Although the mode of action remains unknown, the drug is thought to have potent immunomodulating and anti-inflammatory actions. Recently we have found that immunoglobulin treatment is beneficial upon myocardial diseases with heart failure. In basic aspects, immunoglobulin therapy for experimental viral and non-viral myocarditis has been found to be effective not only by the Fab portion for anti-pathogen effects but by the Fc portion for antiinflammatory effects. Also, the drug was useful for the treatment of experimental murine myocardial disfunction. In clinical aspects, the effect of immunoglobulin administration for fulminant myocarditis and acute dilated cardiomyopathy was investigated. Immunoglobulin administration was very useful for the treatment of such patients. That is, although the study population was small, the drug showed the potential beneficial effects against active myocardial damage with myocardial dysfunction, and the left ventricular ejection fraction of the patients was recovered by the treatment. Accordingly, immunoglobulin treatment for patients with heart appears to be novel and effective treatment strategies.